These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 28797568)
21. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463 [TBL] [Abstract][Full Text] [Related]
22. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Danks MK; Garrett KE; Marion RC; Whipple DO Cancer Res; 1996 Apr; 56(7):1664-73. PubMed ID: 8603418 [TBL] [Abstract][Full Text] [Related]
23. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476 [TBL] [Abstract][Full Text] [Related]
24. ATM is required for the repair of Topotecan-induced replication-associated double-strand breaks. Köcher S; Spies-Naumann A; Kriegs M; Dahm-Daphi J; Dornreiter I Radiother Oncol; 2013 Sep; 108(3):409-14. PubMed ID: 23928469 [TBL] [Abstract][Full Text] [Related]
25. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Lamond JP; Wang M; Kinsella TJ; Boothman DA Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):369-76. PubMed ID: 8892462 [TBL] [Abstract][Full Text] [Related]
26. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. Wildner O; Blaese RM; Morris JC Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896 [TBL] [Abstract][Full Text] [Related]
27. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. Tomicic MT; Christmann M; Kaina B J Pharmacol Exp Ther; 2010 Jan; 332(1):316-25. PubMed ID: 19812371 [TBL] [Abstract][Full Text] [Related]
28. [Killing and proapoptotic effects of topoisomerase I inhibitor on K562 cells]. Chen XQ; Wan YF; Bai QX; Cao YX Ai Zheng; 2002 Apr; 21(4):356-9. PubMed ID: 12452010 [TBL] [Abstract][Full Text] [Related]
29. Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts. Pinel S; Chastagner P; Merlin JL; Marchal C; Taghian A; Barberi-Heyob M J Neurooncol; 2006 Jan; 76(1):31-8. PubMed ID: 16311843 [TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Zhang YW; Regairaz M; Seiler JA; Agama KK; Doroshow JH; Pommier Y Nucleic Acids Res; 2011 May; 39(9):3607-20. PubMed ID: 21227924 [TBL] [Abstract][Full Text] [Related]
32. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Tomicic MT; Christmann M; Kaina B Cancer Res; 2005 Oct; 65(19):8920-6. PubMed ID: 16204064 [TBL] [Abstract][Full Text] [Related]
33. [Interaction of topotecan-a DNA topoisomerase I inhibitor-with dual-stranded polydeoxyribonucleotides. V. Topotecan is able to cause single- and double-strand breaks in ring superhelical DNA in the absence of enzyme]. Grokhovskiĭ SL; Strel'tsov SA; Zhuze AL Mol Biol (Mosk); 2003; 37(6):1045-54. PubMed ID: 14714500 [TBL] [Abstract][Full Text] [Related]
34. Role of resveratrol on the cytotoxic effects and DNA damages of iododeoxyuridine and megavoltage radiation in spheroid culture of U87MG glioblastoma cell line. Firouzi F; Khoei S; Mirzaei HR Gen Physiol Biophys; 2015 Jan; 34(1):43-50. PubMed ID: 25367760 [TBL] [Abstract][Full Text] [Related]
35. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells. Montariello D; Troiano A; Di Girolamo D; Beneke S; Calabrò V; Quesada P Biochem Pharmacol; 2015 Apr; 94(3):212-9. PubMed ID: 25667043 [TBL] [Abstract][Full Text] [Related]
36. Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN. Zhang M; Shan BE; Yuan NF; Liu W Chin Med J (Engl); 2013 Jan; 126(2):340-4. PubMed ID: 23324287 [TBL] [Abstract][Full Text] [Related]
37. The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line. Zhang J; Cheng C; He CL; Zhou YJ; Cao Y Cancer Invest; 2008 Jun; 26(5):456-63. PubMed ID: 18568767 [TBL] [Abstract][Full Text] [Related]
38. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Mattern MR; Hofmann GA; McCabe FL; Johnson RK Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371 [TBL] [Abstract][Full Text] [Related]
39. Targeting Topoisomerase I in the Era of Precision Medicine. Thomas A; Pommier Y Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499 [TBL] [Abstract][Full Text] [Related]
40. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Smith LM; Willmore E; Austin CA; Curtin NJ Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]